Psilocybin-Assisted Therapy for Depression and Alcoholism

This trial tests psilocybin-assisted therapy to determine its safety and effectiveness for individuals with both major depression and alcohol use disorder. Participants will receive either a psilocybin capsule or a placebo to compare differences in their feelings and adherence to the treatment. It suits those with moderate to severe depression and alcohol issues who are not seeking traditional medications for these conditions. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to important early-stage findings.

Yes, you will need to stop taking certain medications, including antidepressants, antipsychotics, anti-alcohol/anti-craving medications, and some enzyme inhibitors, at least 2 weeks before starting the trial and for its duration, if your doctor confirms it's safe.

Research has shown that psilocybin is generally safe for people with major depressive disorder (MDD). One study found that a 25 mg dose of psilocybin, when combined with therapy, helped treat MDD without causing any serious unexpected side effects. Another study demonstrated that psilocybin remained safe and effective for up to five years, with no major problems reported. These findings suggest that psilocybin could be a safe option for people with MDD, especially when used with proper support and guidance.¹²³⁴⁵

Unlike traditional treatments for depression and alcoholism, which often include antidepressants like SSRIs and addiction medications like naltrexone, psilocybin offers a novel approach through its action on serotonin receptors in the brain. Psilocybin is derived from certain mushrooms, and it is thought to promote new neural connections, potentially leading to more profound and lasting improvements in mental health. Researchers are excited because psilocybin may provide rapid relief from symptoms, sometimes within just a few sessions, compared to the weeks or months required for standard medications. Additionally, the unique experience facilitated by psilocybin-assisted therapy could help individuals gain new perspectives on their mental health challenges, offering a holistic approach that extends beyond mere symptom management.

Studies have shown that psilocybin can help reduce symptoms of Major Depressive Disorder (MDD). Research suggests that a 25 mg dose of psilocybin, which participants in this trial may receive, can significantly improve depression symptoms over time. Another study found that psilocybin therapy led to a substantial and lasting decrease in depression. Although the long-term effects are still under investigation, these early results appear promising. Additionally, patients have reported few side effects, indicating it might be a safe option for treating these conditions.¹³⁴⁵⁶